--- title: "INmune Bio (NASDAQ:INMB) Posts Earnings Results" description: "INmune Bio (NASDAQ:INMB) reported quarterly earnings of ($0.40) per share, exceeding analysts' expectations of ($0.54) by $0.14. The stock traded down to $7.14, with a market cap of $189.86 million. A" type: "news" locale: "en" url: "https://longbridge.com/en/news/233732690.md" published_at: "2025-03-29T14:45:33.000Z" --- # INmune Bio (NASDAQ:INMB) Posts Earnings Results > INmune Bio (NASDAQ:INMB) reported quarterly earnings of ($0.40) per share, exceeding analysts' expectations of ($0.54) by $0.14. The stock traded down to $7.14, with a market cap of $189.86 million. Analysts have given the stock a consensus rating of "Buy" with a target price of $22.80. Recent upgrades include Maxim Group raising their target from $22.00 to $30.00 and Scotiabank increasing theirs from $22.00 to $23.00. INmune Bio focuses on developing drugs to treat various diseases by reprogramming the immune system. INmune Bio (NASDAQ:INMB - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.14, Zacks reports. ## INmune Bio Price Performance Shares of INMB traded down $0.27 during mid-day trading on Friday, reaching $7.14. 61,057 shares of the company's stock were exchanged, compared to its average volume of 241,182. The stock has a market capitalization of $189.86 million, a PE ratio of -3.25 and a beta of 1.93. The business's fifty day simple moving average is $8.39 and its 200-day simple moving average is $6.37. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72. ## Analyst Upgrades and Downgrades Several research firms have weighed in on INMB. Maxim Group lifted their target price on INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Scotiabank increased their target price on INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They set a "buy" rating and a $23.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $22.80. **View Our Latest Analysis on INMB** ## About INmune Bio (Get Free Report) INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. ## See Also - Five stocks we like better than INmune Bio - Stock Sentiment Analysis: How it Works - Buy the Chewy Stock Reversal? Here’s Why Now Is the Time - How Technical Indicators Can Help You Find Oversold Stocks - Ibotta Stock: Why the Buyback Looks Like a Bullish Bet - What is the S&P 500 and How It is Distinct from Other Indexes - Joby Aviation Stock: Analyst Confidence and Smart Money Align *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in INmune Bio Right Now? Before you consider INmune Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list. While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [INMB.US - Inmune Bio](https://longbridge.com/en/quote/INMB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 在近期股价疲软和长期回报压力下评估 Bio-Rad（BIO）的估值 | Bio-Rad 实验室（BIO）经历了显著的股价下跌，促使对其估值进行重新评估。目前股价为 256.56 美元，相较于 348 美元的公允价值估计，该股票被认为是被低估的。尽管面临近期挑战，包括三年内总股东回报下降 46.91%，Bio-R | [Link](https://longbridge.com/en/news/275997412.md) | | INmune Bio：基于生物标志物的阿尔茨海默症试验设计及管线催化剂支持买入评级 | Maxim Group 的分析师 Jason McCarthy 对 Inmune Bio 维持了买入评级，目标价为 8.00 美元。该评级得益于公司在早期阿尔茨海默病试验中的进展，特别是 FDA 批准的 2b/3 期试验，该试验使用了生物标 | [Link](https://longbridge.com/en/news/275941900.md) | | MiniMax 发布 M2.5 模型：1 美元运行 1 小时，价格仅为 GPT-5 的 1/20，性能比肩 Claude Opus | M2.5 模型实现性能与成本的双重突破。价格仅为 GPT-5 等主流模型的 1/10 至 1/20。性能比肩 Claude Opus，在多语言编程测试 Multi-SWE-Bench 夺冠，任务完成速度较上代提升 37%。采用原生 Agen | [Link](https://longbridge.com/en/news/275838132.md) | | OpenAI 高管：工程师变成 “魔法师”，AI 将开启新一轮创业狂潮 | OpenAI 内部曝光：95% 工程师已用 AI 编程，代码审查全由 Codex 接管！负责人 Sherwin Wu 预言，未来两年模型将具备数小时长任务处理能力，工程师正变为指挥智能体的 “巫师”。随着模型吞噬中间层，为 “超级个体” 服 | [Link](https://longbridge.com/en/news/275998627.md) | | 编程 AI 又变天？神秘模型 Pony Alpha 火了，被曝是智谱 GLM-5，股价两日暴涨 60%！ | 代号 “Pony Alpha” 的高性能模型被广泛推测为智谱 AI 新一代旗舰产品 GLM-5，推动其股价两日暴涨 60%、市值突破 1500 亿港元。技术测试显示该模型在架构与能力上与 GLM 系列高度一致，其展现的高端编程与智能体水平被 | [Link](https://longbridge.com/en/news/275441413.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.